Serbia Pharmaceuticals and Healthcare Report - Business Monitor International - Industry Reports

Serbia Pharmaceuticals and Healthcare Report

Serbia Pharmaceuticals and Healthcare Report - Business Monitor International - Industry Reports
Serbia Pharmaceuticals and Healthcare Report
Published Jun 25, 2016
79 pages — Published Jun 25, 2016
Price US$ 1,295.00  |  Buy this Report Now

About This Report

  
Abstract:

In our Q--- Pharmaceutical Risk/Reward Index (RRI), Serbia is ranked --th out of -- markets in the Central and Eastern European (CEE) matrix with a downgraded score of --.- compared with the previous quarter (--.-). Its position remains unchanged in the matrix despite a worse score, above Uzbekistan (--.-) and below Kazakhstan (--.-). ...In our Q--- Pharmaceutical Risk/Reward Index (RRI), Serbia is ranked --th out of -- markets in the Central and Eastern European (CEE) matrix with a downgraded score of --.- compared with the previous quarter (--.-). Its position remains unchanged in the matrix despite a worse score, above Uzbekistan (--.-) and below Kazakhstan (--.-). Serbia scores considerably below the regional average score of --.- in Q---. ...Serbia scores considerably below the regional average score of --.- in Q---. Serbia will continue to be a challenging market for foreign investors, because of the prevalence of corruption, a large-scale black-market economy, and the poor state of the country s infrastructure and finances, in both public and private spheres.

...Gradual integration with the EU and the prospect of accession will stimulate reform. EU accession and IMF reform agenda to liberalise trade, align legislation with EU norms and open economy up to competition. ...EU accession and IMF reform agenda to liberalise trade, align legislation with EU norms and open economy up to competition. Funding issues and the relatively low level of domestic industry are providing substantial opportunities for imported generic products, as well as local production destined for export. An abridged application procedure for generic products providing opportunities for generic drug manufacturers, both domestic and foreign. ...An abridged application procedure for generic products providing opportunities for generic drug manufacturers, both domestic and foreign. Direct-to-pharmacy sales by manufacturers legalised in order to resolve some of the healthcare debts.

...BMI View: Although Serbia s pharmaceutical market represents high growth potential given its underdevelopment in comparison to its Eastern European neighbours, a number of market challenges will lead to poor long-term growth in medicine sales. The country s poor economic outlook and the depreciation of the dinar over the past two years will limit consumer spending power and reduce revenue-earning opportunities for foreign firms. ...

  
Source:
Document ID
1748-2151
Industry
Format:
PDF Adobe Acrobat
Buy Now

Business Monitor International - Industry Reports—Established in 1984, Business Monitor International is a leading online publisher of specialist business information on global emerging markets. Business Monitor's range of quarterly services covers political risk, finance, macroeconomic performance, outlook and forecast, industry sectors and the business operating environment. Each Industry Report has been researched at source, and features latest-available data covering production, sales, imports and exports; 5-year industry forecasts through end-2012; company rankings and competitive landscapes for multinational and local manufacturers and suppliers; and analysis of latest industry developments, trends and regulatory changes.

About the Author


Cite this Report

  
MLA:
Business Monitor International - Industry Reports. "Serbia Pharmaceuticals and Healthcare Report" Jun 25, 2016. Alacra Store. Dec 05, 2016. <http://www.alacrastore.com/storecontent/Business-Monitor-International-Industry-Reports/Serbia-Pharmaceuticals-and-Healthcare-Report-2026-299>
  
APA:
Business Monitor International - Industry Reports. (2016). Serbia Pharmaceuticals and Healthcare Report Jun 25, 2016. New York, NY: Alacra Store. Retrieved Dec 05, 2016 from <http://www.alacrastore.com/storecontent/Business-Monitor-International-Industry-Reports/Serbia-Pharmaceuticals-and-Healthcare-Report-2026-299>
  
US$ 1,295.00
$  £  
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.